PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24698107-0	2014	Loss of B-cell translocation gene 2 expression in estrogen receptor-positive breast cancer predicts tamoxifen resistance.	Tamoxifen	100-109	BTG anti-proliferation factor 2	Homo sapiens	8-35	
24698107-0	2014	Loss of B-cell translocation gene 2 expression in estrogen receptor-positive breast cancer predicts tamoxifen resistance.	Tamoxifen	100-109	estrogen receptor 1	Homo sapiens	50-67	
24698107-2	2014	BTG2 inhibits the expression of HER ligands and promotes AKT activation, which plays an essential role in the tamoxifen resistance of estrogen receptor (ER)-positive breast cancer.	Tamoxifen	110-119	BTG anti-proliferation factor 2	Homo sapiens	0-4	
24698107-2	2014	BTG2 inhibits the expression of HER ligands and promotes AKT activation, which plays an essential role in the tamoxifen resistance of estrogen receptor (ER)-positive breast cancer.	Tamoxifen	110-119	AKT serine/threonine kinase 1	Homo sapiens	57-60	
24698107-2	2014	BTG2 inhibits the expression of HER ligands and promotes AKT activation, which plays an essential role in the tamoxifen resistance of estrogen receptor (ER)-positive breast cancer.	Tamoxifen	110-119	estrogen receptor 1	Homo sapiens	134-151	
24698107-2	2014	BTG2 inhibits the expression of HER ligands and promotes AKT activation, which plays an essential role in the tamoxifen resistance of estrogen receptor (ER)-positive breast cancer.	Tamoxifen	110-119	estrogen receptor 1	Homo sapiens	33-35	
24698107-5	2014	Tamoxifen suppressed the human epidermal growth factor receptor 2 (HER2)-Akt signaling in BTG2 expressing ER-positive breast cancer cells with a correlated increase in sensitivity, whereas BTG2 knockdown abrogated this sensitivity.	Tamoxifen	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	25-65	
24698107-5	2014	Tamoxifen suppressed the human epidermal growth factor receptor 2 (HER2)-Akt signaling in BTG2 expressing ER-positive breast cancer cells with a correlated increase in sensitivity, whereas BTG2 knockdown abrogated this sensitivity.	Tamoxifen	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-71	
24698107-5	2014	Tamoxifen suppressed the human epidermal growth factor receptor 2 (HER2)-Akt signaling in BTG2 expressing ER-positive breast cancer cells with a correlated increase in sensitivity, whereas BTG2 knockdown abrogated this sensitivity.	Tamoxifen	0-9	AKT serine/threonine kinase 1	Homo sapiens	73-76	
24698107-5	2014	Tamoxifen suppressed the human epidermal growth factor receptor 2 (HER2)-Akt signaling in BTG2 expressing ER-positive breast cancer cells with a correlated increase in sensitivity, whereas BTG2 knockdown abrogated this sensitivity.	Tamoxifen	0-9	BTG anti-proliferation factor 2	Homo sapiens	90-94	
24698107-5	2014	Tamoxifen suppressed the human epidermal growth factor receptor 2 (HER2)-Akt signaling in BTG2 expressing ER-positive breast cancer cells with a correlated increase in sensitivity, whereas BTG2 knockdown abrogated this sensitivity.	Tamoxifen	0-9	estrogen receptor 1	Homo sapiens	68-70	
24698107-6	2014	Consistent with this observation, tamoxifen significantly suppressed the growth ratio, tumor weight and Ki-67 expression in BTG2 expressing breast cancer xenografts in mice.	Tamoxifen	34-43	BTG anti-proliferation factor 2	Mus musculus	124-128	
24698107-7	2014	These studies demonstrate that BTG2 is a significant factor in tamoxifen response, acting through modification of AKT activation in ER-positive/HER2-negative breast cancer.	Tamoxifen	63-72	BTG anti-proliferation factor 2	Homo sapiens	31-35	
24698107-7	2014	These studies demonstrate that BTG2 is a significant factor in tamoxifen response, acting through modification of AKT activation in ER-positive/HER2-negative breast cancer.	Tamoxifen	63-72	AKT serine/threonine kinase 1	Homo sapiens	114-117	
24698107-7	2014	These studies demonstrate that BTG2 is a significant factor in tamoxifen response, acting through modification of AKT activation in ER-positive/HER2-negative breast cancer.	Tamoxifen	63-72	estrogen receptor 1	Homo sapiens	132-134	
24698107-7	2014	These studies demonstrate that BTG2 is a significant factor in tamoxifen response, acting through modification of AKT activation in ER-positive/HER2-negative breast cancer.	Tamoxifen	63-72	erb-b2 receptor tyrosine kinase 2	Homo sapiens	144-148